

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>ixekizumab</b>
Brand Name	Taltz™
Dosage Forms	80 mg/1 mL pre-filled autoinjector and pre-filled syringe
Manufacturer	Eli Lilly Canada Inc.
<b>Submission Type</b>	<b>New Submission</b>
Use Reviewed	For the treatment of adult patients with moderate to severe plaque psoriasis.
Common Drug Review (CDR)	Yes, CDR recommended: <b>to Reimburse with clinical criteria and/or conditions</b> . Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0481_complete_Taltz-oct-27-16.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0481_complete_Taltz-oct-27-16.pdf</a>
Provincial Review	The Drug Benefit Council (the DBC) now screens drug submissions under review by the Common Drug Review (CDR) to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision is based on the Canadian Drug Expert Committee (CDEC) recommendation and a provincial internal review only. On May 2, 2016, the DBC screened ixekizumab for moderate to severe plaque psoriasis and advised that because ixekizumab is similar to other biologics used for the treatment of plaque psoriasis, the Ministry may accept the CDEC's recommendation for ixekizumab.
<b>Drug Coverage Decision</b>	<b>Limited Coverage Benefit. Access the ixekizumab criteria from</b> <a href="http://www.gov.bc.ca/pharmacarespecialauthority">www.gov.bc.ca/pharmacarespecialauthority</a>
Date	March 6, 2018
Reasons	<b>Drug coverage decision is consistent with the CDEC recommendation.</b> <ul style="list-style-type: none"> <li>• The drug demonstrated some advantage over placebo and etanercept with respect to improvements in Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI) 75 scores after 12 weeks of treatment.</li> <li>• The drug was associated with improvements in health-related quality of life and functionality as compared to placebo and etanercept.</li> <li>• The drug was similar to etanercept with respect to safety.</li> <li>• The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.